BREAKTHROUGHS IN RECOMBINANT HUMAN SERUM ALBUMIN FOR BIOPHARMACEUTICAL PROGRAMS

Recombinant human serum albumin (OsrHSA) has emerged as a major innovation in the sector of biopharmaceuticals, giving promising advancements across several clinical and industrial programs. With its structural similarity to naturally derived human serum albumin, OsrHSA provides a safer, extra reliable alternative for therapeutic use, especially in